New England Asset Management Inc. trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 29.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 970 shares of the medical research company’s stock after selling 400 shares during the quarter. New England Asset Management Inc.’s holdings in Amgen were worth $159,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. TrimTabs Asset Management LLC raised its position in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC raised its position in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC bought a new stake in shares of Amgen during the 1st quarter worth about $121,000. Finally, Signature Estate & Investment Advisors LLC raised its position in shares of Amgen by 13.6% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after buying an additional 95 shares in the last quarter. Institutional investors own 78.13% of the company’s stock.

Amgen Inc. (AMGN) traded down 0.04% during mid-day trading on Friday, hitting $180.64. 1,993,947 shares of the company traded hands. The company’s 50-day moving average price is $173.77 and its 200 day moving average price is $168.79. The company has a market capitalization of $131.81 billion, a price-to-earnings ratio of 16.45 and a beta of 1.35. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the prior year, the business earned $2.84 EPS. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were paid a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.55%. Amgen’s payout ratio is 41.93%.

A number of analysts have commented on AMGN shares. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Finally, Argus boosted their price target on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and a consensus target price of $186.04.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/09/amgen-inc-amgn-holdings-lowered-by-new-england-asset-management-inc.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.